Compare PayPal Holdings, Inc. (PYPL) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
PayPal Holdings, Inc. vs TG Therapeutics Inc — how do they compare? PayPal Holdings, Inc. trades at $55.52 (market cap $49.27B), while TG Therapeutics Inc trades at $52.7 (market cap $8.26B). The key difference: PayPal Holdings, Inc. is far larger — about 6× TG Therapeutics Inc's market cap, and PayPal Holdings, Inc. pays a 1% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| PYPL | TGTX | |
|---|---|---|
Market Cap | $49.27B | $8.26B |
Sector | Financials | Health |
52-Week High | $78.22 | $59.06 |
52-Week Low | $39.08 | $26.39 |
Enterprise Value | $49.33B | $8.50B |
Dividend Yield | 1% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PayPal (PYPL) trades at $55.85, down 1.26% today, amid takeover speculation from Stripe and Advent International. The stock shows strong fundamentals with a P/E of 10.66 and net income margin of 15%, while technical indicators are mixed with a bullish moving average signal but overbought RSI levels. Recent earnings beat expectations in Q1 2026, and the company maintains robust cash flow from operations of $6.42 billion in 2025.
The outlook is clouded by the potential buyout, which could limit upside if the offer is rejected, while profitability pressures and competition from Apple Pay pose risks. Analyst consensus is cautious with a hold-heavy rating, suggesting investors await clarity on strategic direction amid the takeover bid.
TG Therapeutics (TGTX) trades at $53.96, down 1.6% today, with a bullish technical signal and strong profitability metrics including a 65.95% net income margin. Recent news highlights clinical progress, including a Phase 2 trial for Briumvi in schizophrenia (Zacks Investment Research, 2026-07-07) and positive Phase 1 data for subcutaneous Briumvi (GlobeNewsWire, 2026-06-03). However, earnings misses in Q4 2025 and Q1 2026 and a shareholder investigation (PRNewsWire, 2026-07-21) introduce volatility.
The outlook is mixed: analyst consensus is strongly bullish (84.6% buy ratings) with a $48.50 price target, but near-term risks from legal scrutiny and earnings inconsistency warrant caution. Upside hinges on successful drug trials and sales growth, while downside risks include legal outcomes and competitive pressures in the biotech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About PayPal Holdings, Inc.
PayPal Holdings, Inc. operates as a technology platform company that enables digital and mobile payments on behalf of consumers and merchants. The Company offers online payment solutions. PayPal Holdings serves customers worldwide.
Read more on PYPL →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
